New Approaches to Improved Vaccine Manufacturing in Embryonated Eggs - Recombinant vector technologies can improve the yield and lower the cost of egg-based influenza vaccine production. - BioPharm

ADVERTISEMENT

New Approaches to Improved Vaccine Manufacturing in Embryonated Eggs
Recombinant vector technologies can improve the yield and lower the cost of egg-based influenza vaccine production.


BioPharm International Supplements


Effect on the Organization of Vaccine Production


Figure 3. Comparison of estimated timelines for influenza vaccine development and manufacture using recombinant vectors versus live influenza virus.2
Upgrading the embryonated egg platform with the technologies and systems described here could help to update the flu vaccine manufacturing process. The shorter lead time needed for producing an AdCEV production vector would offer near real-time development of vaccines for emerging pathogen strains. Vector technologies can reduce the time from strain isolation to full-scale flu vaccine production from the current norm of 28 weeks to 20 weeks (Figure 3).

AdCEV vectors are being optimized for use within the framework of small- to medium-scale facilities that can manufacture a mix of products targeting state, national, or regional biopharmaceutical markets for added sustainability. Such a manufacturing system adds a long sought-after component to the global influenza surveillance and manufacturing system by offering the potential for rapid, regional level responses to the threat of rapidly evolving strains of pathogenic influenza.

Funding Surge Capacity from Other Market Opportunities

Financing an increase in global flu vaccine manufacturing capacity requires infrastructure to sustain preparedness, and to rapidly surge production. The cost of implementing upgrades to vaccine production as outlined by the WHO is estimated at $3–10 billion and depends heavily on private sector investment and the commitment of existing manufacturers.4 Manufacturers have responded to the current swine flu pandemic generously, committing nearly 157 million of the estimated 200 million dose target set by the WHO for immunization of target populations in poor countries.9 Using the AdCEV/egg platform, the growing demand for recombinant products in diagnostics and research reagent industries can be used as an economic foundation for sustaining pandemic preparedness. Five non-vaccine biologic market segments could sustain the growth of a global vaccine manufacturing network: human biologics, human diagnostics, agricultural, specialties, and non-medical diagnostics. They offer products with market values ranging from $5 to 20,000 per mg of recombinant protein, which is an amount reasonably produced in a single chicken egg using AdCEV technology.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here